SEC Comment Letter 0000000000-24-005076 to Inmune Bio, Inc. (INMB) (CIK 0001711754) (INMB)
Inmune Bio, Inc. (INMB) (CIK 0001711754)
Date: May 3, 2024 · CIK: 0001711754 · Accession: 0000000000-24-005076
AI Filing Summary & Sentiment
File numbers found in text: 333-279036
Letter
United States securities and exchange commission logo May 3, 2024 David Moss Chief Financial Officer INmune Bio, Inc. 225 NE Mizner Blvd., Suite 640 Boca Raton, FL 33432 Re:INmune Bio, Inc. Registration Statement on Form S-3 Filed May 1, 2024 File No. 333-279036 Dear David Moss: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Manno, Esq.
Show Raw Text
United States securities and exchange commission logo
May 3, 2024
David Moss
Chief Financial Officer
INmune Bio, Inc.
225 NE Mizner Blvd., Suite 640
Boca Raton, FL 33432
Re:INmune Bio, Inc.
Registration Statement on Form S-3
Filed May 1, 2024
File No. 333-279036
Dear David Moss:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David Manno, Esq.